We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Technique Detects Genetic Mutations in Brain Tumors During Surgery within 25 Minutes

By LabMedica International staff writers
Posted on 21 Oct 2025

Determining the genetic profile of brain tumors during surgery is crucial for improving patient outcomes, but conventional analysis methods can take up to two days, delaying critical decisions. More...

Surgeons often operate without real-time molecular data, making it difficult to identify tumor boundaries or tailor the extent of removal. Now, a new genetic testing system enables the detection of key brain tumor mutations in as little as 25 minutes, allowing immediate guidance during surgery.

Developed by researchers at Nagoya University (Nagoya, Japan), the system uses the GeneSoC high-speed real-time PCR device, which incorporates advanced microfluidic technology. The team designed an original protocol enabling high-quality DNA extraction using only heat incubation, eliminating lengthy preparation steps. This combination allows for ultra-fast, on-site genetic testing directly from tumor samples collected during surgery.

The system was tested on 120 cases of brain tumors to detect mutations in isocitrate dehydrogenase (IDH1) and telomerase reverse transcriptase (TERT) promoters—key diagnostic markers for diffuse glioma. Results showed remarkable accuracy, with 98.5% sensitivity and 98.2% specificity for IDH1, and 100% for TERT mutation detection. The average testing time per sample was just 22−25 minutes, as reported in Neuro-Oncology.

By identifying genetic mutations intraoperatively, surgeons can more precisely define tumor margins and distinguish cancerous tissue from normal brain cells. This approach could improve surgical outcomes by maximizing tumor removal while minimizing damage to healthy tissue. The researchers also confirmed that the system accurately defines tumor boundaries, a critical step for surgical decision-making.

“We demonstrated that our genetic analysis system enables molecular diagnosis during surgery. This system identifies tumor boundaries, helping surgeons define resection margins. This marks a significant clinical achievement,” said researcher Sachi Maeda. “Notably, our system's ability to intraoperatively identify TERT promoter mutations—which cannot be detected through immunostaining—represents a groundbreaking advancement globally. We believe this technology will significantly enhance the precision of glioma surgery in the near future.”

Related Links:
Nagoya University


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Clinical Chemistry System
P780
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.